2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1273

Uptake of the First Biosimilar Infliximab Since Its Approval in South Korea
Abstract Number: 229

Uric Acid and Incident Dementia over 10 Years
Abstract Number: 231

Uric Acid Levels Predict Mortality in Women
Abstract Number: 2342

Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Abstract Number: 2070

Urinary Biomarker Based “a-RAIL”� Study in Adults with Lupus Nephritis
Abstract Number: 385

Urinary Cell-Free Microrna’s As Biomarkers of Lupus Nephritis in Children
Abstract Number: 718

Urinary MBL : A Promising Biomarker for Predicting Flare in Lupus Nephritis
Abstract Number: 2071

Urinary Osteoprotegerin As Biomarker of Lupus Nephritis Disease Activity: Cross Sectional and Longitudinal Study
Abstract Number: 2905

Urinary Protein:Urinary Creatinine Ratio in an Untimed Urine Specimen and Estimated Glomerular Filtration Rate Are Reliable Measures of Proteinuria and Renal Function in Patients with Lupus Nephritis
Abstract Number: 716

Urinary Proteomics Identifies Three Novel Biomarkers for Lupus Nephritis Activity: Retinol Binding Protein, Alpha-1-Antichymotrysin and Haptoglobin
Abstract Number: 1277

US Adult Rheumatologists Perspective on the Transition Process for Young Adults with Rheumatic Conditions
Abstract Number: 442

Use of Adjunctive Neuroregulatory Medication to Improve Etanercept Treatment Response for Patients with Inflammatory Arthritis: A Pilot Study
Abstract Number: 1200

Use of Focus Groups and Patient Partners to Revise an Internet Self-Management Program
Abstract Number: 2484

Use of Lean Six Sigma Methodology to Improve Time to Scheduling for New Patient Referrals to Rheumatology
Abstract Number: 2365

Use of Long Term Subscutaneous Immunoglobulins in Inflammatory Myopathies: A Retrospective Analysis of 19 Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].